Fosun Pharma Subsidiary Secures NMPA Green Light for Pediatric Constipation Treatment

Bulletin Express17:46

Shanghai Fosun Pharmaceutical (Fosun Pharma) announced that its wholly owned unit, Suzhou Erye Pharmaceutical, has obtained National Medical Products Administration approval to market Polyethylene Glycol (3350) and Electrolytes Powder in mainland China.

The powder formulation, registered as a Category 3 chemical drug under approval number Guo Yao Zhun Zi H202654072, is indicated for: 1. Treatment of chronic constipation in children aged 1–11 years. 2. Treatment of faecal impaction in children from 5 years of age.

Development outlays for the product totaled approximately RMB2.62 million as of June 2026. According to IQVIA CHPA data, mainland‐China sales of comparable polyethylene glycol electrolyte powders reached about RMB598 million in 2025, underscoring a sizeable addressable market.

Management expects the newly approved therapy to broaden Fosun Pharma’s pediatric gastrointestinal portfolio. Nevertheless, future commercial performance will depend on market demand, competitive dynamics and distribution capabilities, factors that may create variability in actual sales outcomes.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162690417?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 17:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162690417","market":"hk","top_or_hot":-1,"title":"Fosun Pharma Subsidiary Secures NMPA Green Light for Pediatric Constipation Treatment","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Fosun Pharma) announced that its wholly owned unit, Suzhou Erye Pharmaceutical, has obtained National Medical Products Administration approval to market Polyethylene Glycol (3350) and Electrolytes Powder in mainland China.</p>\n<p>The powder formulation, registered as a Category 3 chemical drug under approval number Guo Yao Zhun Zi H202654072, is indicated for:\n1. Treatment of chronic constipation in children aged 1–11 years.\n2. Treatment of faecal impaction in children from 5 years of age.</p>\n<p>Development outlays for the product totaled approximately RMB2.62 million as of June 2026. According to IQVIA CHPA data, mainland‐China sales of comparable polyethylene glycol electrolyte powders reached about RMB598 million in 2025, underscoring a sizeable addressable market.</p>\n<p>Management expects the newly approved therapy to broaden Fosun Pharma’s pediatric gastrointestinal portfolio. Nevertheless, future commercial performance will depend on market demand, competitive dynamics and distribution capabilities, factors that may create variability in actual sales outcomes.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma Subsidiary Secures NMPA Green Light for Pediatric Constipation Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma Subsidiary Secures NMPA Green Light for Pediatric Constipation Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-03 17:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Fosun Pharma) announced that its wholly owned unit, Suzhou Erye Pharmaceutical, has obtained National Medical Products Administration approval to market Polyethylene Glycol (3350) and Electrolytes Powder in mainland China.</p>\n<p>The powder formulation, registered as a Category 3 chemical drug under approval number Guo Yao Zhun Zi H202654072, is indicated for:\n1. Treatment of chronic constipation in children aged 1–11 years.\n2. Treatment of faecal impaction in children from 5 years of age.</p>\n<p>Development outlays for the product totaled approximately RMB2.62 million as of June 2026. According to IQVIA CHPA data, mainland‐China sales of comparable polyethylene glycol electrolyte powders reached about RMB598 million in 2025, underscoring a sizeable addressable market.</p>\n<p>Management expects the newly approved therapy to broaden Fosun Pharma’s pediatric gastrointestinal portfolio. Nevertheless, future commercial performance will depend on market demand, competitive dynamics and distribution capabilities, factors that may create variability in actual sales outcomes.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1162690417","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162690417","pubTimestamp":1785750417,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Fosun Pharma) announced that its wholly owned unit, Suzhou Erye Pharmaceutical, has obtained National Medical Products Administration approval to market Polyethylene...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药子公司获得NMPA批准治疗儿童便秘","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Fosun Pharma) announced that its wholly owned unit, Suzhou Erye Pharmaceutical, has obtained National Medical Products Administration approval to market Polyethylene Glycol (3350) and Electrolytes Powder in mainland China.\nThe powder formulation, registered as a Category 3 chemical drug under approval number Guo Yao Zhun Zi H202654072, is indicated for:\n1. Treatment of chronic constipation in children aged 1–11 years.\n2. Treatment of faecal impaction in children from 5 years of age.\nDevelopment outlays for the product totaled approximately RMB2.62 million as of June 2026. According to IQVIA CHPA data, mainland‐China sales of comparable polyethylene glycol electrolyte powders reached about RMB598 million in 2025, underscoring a sizeable addressable market.\nManagement expects the newly approved therapy to broaden Fosun Pharma’s pediatric gastrointestinal portfolio. Nevertheless, future commercial performance will depend on market demand, competitive dynamics and distribution capabilities, factors that may create variability in actual sales outcomes.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.0","shortVersion":"4.47.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162690417","isCrawlerRequest":true}